Intrinsic Value of S&P & Nasdaq Contact Us

Incyte Corporation INCY NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
82/100
6/7 Pass
SharesGrow Intrinsic Value
$117.61
+20.4%
Analyst Price Target
$108.90
+11.5%

Incyte Corporation (INCY) generated $1.41B in operating cash flow for fiscal year 2025. After capital expenditures of $58.87M, free cash flow was $1.35B.

Free cash flow margin was 26.3% of revenue. Cash conversion ratio was 1.1x, indicating earnings are backed by cash.

The company returned $19.1M in share buybacks to shareholders during the period.

Criteria supported by this page:

  • HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
  • MOAT (71/100, Pass) — $1.35B (26.3% FCF margin) supports a durable competitive advantage
  • INCOME (85/100) — Cash conversion ratio was 1.1x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 82/100 with 6/7 criteria passed.

SharesGrow 7-Criteria Score
82/100
SG Score
View full scorecard →
VALUE
77/100
Price-to-Earnings & upside
→ Valuation
~
FUTURE
52/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
71/100
Proven by this page
GROWTH
90/100
→ Income
INCOME
85/100
→ Income
Incyte Corporation Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2022
Operating Cash Flow $1.41B$1.41B$335.34M$496.49M$969.94M
Capital Expenditure $-58.87M$-58.87M$-86.26M$-47.49M$-77.83M
Free Cash Flow $1.35B$1.35B$249.07M$449M$892.11M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message